Retraction Note: The microRNA-130a-5p/RUNX2/STK32A network modulates tumor invasive and metastatic potential in non-small cell lung cancer

Affiliations

¹ Department of Oncology, the Second Xiangya Hospital of Central South University, No. 139, Renmin Middle Road, Furong District, Changsha, 410000, Hunan, P.R. China.
² Department of Oncology, Zhuzhou 331 Hospital, Zhuzhou, 412000, Hunan, P.R. China.
³ Department of Oncology, the Second Xiangya Hospital of Central South University, No. 139, Renmin Middle Road, Furong District, Changsha, 410000, Hunan, P.R. China. liuxianling@csu.edu.cn.

Fang Ma et al. BMC Cancer. 2025.

. 2025 Jul 22;25(1):1198.

doi: 10.1186/s12885-025-14700-0.

¹ Department of Oncology, the Second Xiangya Hospital of Central South University, No. 139, Renmin Middle Road, Furong District, Changsha, 410000, Hunan, P.R. China.
² Department of Oncology, Zhuzhou 331 Hospital, Zhuzhou, 412000, Hunan, P.R. China.
³ Department of Oncology, the Second Xiangya Hospital of Central South University, No. 139, Renmin Middle Road, Furong District, Changsha, 410000, Hunan, P.R. China. liuxianling@csu.edu.cn.

No abstract available

Retraction of

The microRNA-130a-5p/RUNX2/STK32A network modulates tumor invasive and metastatic potential in non-small cell lung cancer.
Ma F, Xie Y, Lei Y, Kuang Z, Liu X. Ma F, et al. BMC Cancer. 2020 Jun 22;20(1):580. doi: 10.1186/s12885-020-07056-0. BMC Cancer. 2020. Retraction in: BMC Cancer. 2025 Jul 22;25(1):1198. doi: 10.1186/s12885-025-14700-0. PMID: 32571328 Free PMC article. Retracted.

1. Zhang C, Ma K, Li WY. RETRACTED: IL-6 promotes Cancer stemness and oncogenicity in U2OS and MG-63 osteosarcoma cells by upregulating the OPN-STAT3 pathway. J Cancer. 2019;10(26):6511–25. 10.7150/jca.29931. Retraction in: J Cancer. 2021;12(23):6948. 10.7150/jca.67290. - PMC - PubMed
1. Yang H, Song Z, Wu X, Wu Y, Liu C. Microrna-652 suppresses malignant phenotypes in glioblastoma multiforme via FOXK1-mediated AKT/mTOR signaling pathway. Onco Targets Ther. 2019;12:5563–75. 10.2147/OTT.S204715. Retraction in: Onco Targets Ther. 2021;14:4935–6. 10.2147/OTT.S340635. - PMC - PubMed
1. Xu L, Li W, Shi Q, Wang M, Li H, Yang X, Zhang J. Microrna–936 inhibits the malignant phenotype of retinoblastoma by directly targeting HDAC9 and deactivating the PI3K/AKT pathway. Oncol Rep. 2020;43(2):635–45. 10.3892/or.2020.7456. Epub 2020 Jan 9. Retraction in: Oncol Rep. 2022;48(4):174. 10.3892/or.2022.8389. - PMC - PubMed